Glenview Trust Co Has $95.89 Million Position in AbbVie Inc. $ABBV

Glenview Trust Co trimmed its position in shares of AbbVie Inc. (NYSE:ABBV) by 1.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 414,149 shares of the company’s stock after selling 7,330 shares during the quarter. AbbVie makes up 1.5% of Glenview Trust Co’s holdings, making the stock its 18th biggest holding. Glenview Trust Co’s holdings in AbbVie were worth $95,892,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Brighton Jones LLC increased its holdings in AbbVie by 17.4% in the fourth quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock valued at $4,072,000 after purchasing an additional 3,401 shares during the period. Revolve Wealth Partners LLC increased its stake in shares of AbbVie by 72.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock valued at $1,294,000 after buying an additional 3,064 shares during the period. Uhlmann Price Securities LLC raised its position in shares of AbbVie by 2.3% during the second quarter. Uhlmann Price Securities LLC now owns 5,130 shares of the company’s stock worth $952,000 after acquiring an additional 116 shares during the last quarter. Balboa Wealth Partners lifted its stake in shares of AbbVie by 17.0% in the second quarter. Balboa Wealth Partners now owns 9,135 shares of the company’s stock worth $1,696,000 after acquiring an additional 1,325 shares during the period. Finally, LMG Wealth Partners LLC boosted its holdings in AbbVie by 0.3% in the second quarter. LMG Wealth Partners LLC now owns 21,722 shares of the company’s stock valued at $4,032,000 after acquiring an additional 59 shares during the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on ABBV shares. UBS Group reduced their price objective on shares of AbbVie from $240.00 to $230.00 and set a “neutral” rating on the stock in a research note on Thursday, February 5th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $223.00 price target on shares of AbbVie in a research report on Wednesday, January 28th. Citigroup lowered their price objective on AbbVie from $235.00 to $230.00 and set a “neutral” rating for the company in a research report on Tuesday, January 27th. Weiss Ratings reissued a “hold (c)” rating on shares of AbbVie in a research note on Wednesday, January 21st. Finally, Sanford C. Bernstein reaffirmed a “market perform” rating on shares of AbbVie in a research note on Thursday, February 5th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $251.00.

AbbVie Price Performance

Shares of ABBV opened at $231.57 on Tuesday. AbbVie Inc. has a one year low of $164.39 and a one year high of $244.81. The company has a market cap of $409.28 billion, a PE ratio of 98.12, a P/E/G ratio of 0.81 and a beta of 0.35. The stock has a 50-day moving average of $223.73 and a 200-day moving average of $221.37.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.65 by $0.06. AbbVie had a negative return on equity of 4,184.47% and a net margin of 6.91%.The business had revenue of $16.62 billion for the quarter, compared to analyst estimates of $16.39 billion. During the same quarter in the prior year, the company earned $2.16 earnings per share. The company’s quarterly revenue was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Analysts expect that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.